看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。- r9 T8 ]9 q/ E n
$ d2 l! p, t5 r5 V2 N7 p' L- ^0 X1 g0 ~7 j7 ~- W: }
Currently available feasibility data for possible combination strategies.
: t1 h3 ~- ~. w& Z( V7 H————————————————————————————————
6 x0 c9 e7 l; z7 g* ICombination Feasibility according to preliminary data x S, q3 T- U5 q
——————————————————————————————————
# X/ |; n$ T1 I5 k, y8 BBevacizumab + sorafenib Yes, reduced dose
2 h! N& \- z9 I" ]; r1 K) `. k( @Bevacizumab + sunitinib† No
; z( O: q# U6 R5 o" ^4 V( p: UBevacizumab + temsirolimus Yes
) q4 z3 u+ X+ h/ O( ^# yBevacizumab + everolimus Yes + f9 e, W9 w3 y( c. j
Sorafenib + sunitinib ? 1 y& U7 U' b5 N. c3 T
Sorafenib + temsirolimus Yes, reduced dose 4 p8 F# r0 K9 F
Sorafenib + everolimus Yes, reduced dose
O9 ~6 }, J$ G' E7 s3 f5 i9 bSunitinib + temsirolimus† No
0 D2 y" _1 w+ p& u# `9 W& [5 S/ G2 \3 B' xSunitinib + everolimus ? ; W6 d; |# s. Z" t) \! q4 `
Temsirolimus + everolimus ? ) @3 @& w1 b* P! B' W
————————————————————
" s, a- ?& u' v6 q T& v' H* m( T; c†Led to US FDA warning.
5 @$ a* N: @ k1 T4 ~) T* b- ^* t?: As yet unattempted combination.
, ~7 b. p' v) _ L+ N# B |